The critical role of interleukin-23 in spondyloarthropathy
Research output: Contribution to journal › Article › peer-review
Colleges, School and Institutes
- Merck Research Laboratories, 901 California Avenue, Palo Alto, CA 94304, USA
The spondyloarthropathies represent highly enigmatic conditions and although their clinical features, anatomical distribution of disease and genetic predisposing factors have been known for some time, a unified concept of the basic pathobiology underlying these illnesses has remained undefined. Recently progress has been made because numerous independent studies have converged upon IL-23 as a central cytokine in spondyloarthropathy and the mechanism and sites of action of this cytokine have now become much clearer. These findings enable the rational design of therapeutic strategies which it is hoped will profoundly modify the progression of these diseases. We will review the anatomical sites affected and the evidence for the importance of IL-23 in these conditions, before drawing these lines of investigation together to propose a model for the unified understanding of spondyloarthropathy.
|Early online date||1 Aug 2013|
|Publication status||Published - Jan 2014|
- Enthesitis, Spondyloarthropathy, Interleukin-23, T lymphocytes